Mutations in PTEN, PIK3CA, KRAS, and β-catenin are frequently seen in type I endometrial cancers, in contrast TP53, ERBB2, p16, and E-cadherin are seen in type II endometrial cancer (71). This evidence concerns the gene ERBB2 and endometrial cancer.